HPG-1860 demonstrates promising preclinical activity in models of NASH
July 28, 2023
Researchers from Hepagene Therapeutics Inc. have disclosed preclinical data for the novel FXR agonist HPG-1860, which is being developed for the treatment of nonalcoholic steatohepatitis (NASH).
